Corporate Profile

Abgenom was formed in 2005 as a privately held biotech R & D company with a mission to improve human health and society by understanding and applying the power of biology to develop breakthrough research technologies and products to improve the human condition, specifically focusing on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value.

Abgenom makes differences by developing innovative products to detect cardiovascular diseases and infectious diseases / zoonoses. Through its immuno- and proteomics research efforts, Abgenom is also identifying and validating novel diagnostic markers, and is seeking to develop diagnostic products based on these markers.

Abgenom owns or has exclusively licensed patents or patent applications covering different technology platforms and their applications, i.e. nano-colloidal gold technologies for developing rapid test devices; Real-time qPCR for rapid detecting various pathogens simultaneously; and integrated diagnostic chips to simultaneously detect various pathogens, virus and antibodies. As regard to applications, our patents cover different groups of diseases such as cardiovascular disease, STD, virus hepatitis, rabies virus, and multiple HIV antibodies.

Abgenom’s products also serve the needs of some markets outside of life science research, which we refer to as “applied markets,” such as the fields of human good prenatal and postnatal care (early pregnancy, ovulation and sterility testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food, feed and the environment.